Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Global MicroRNA Expression Profiling Identifies Unique MicroRNA Pattern of Radioresistant Glioblastoma Cells

J. Ondracek, P. Fadrus, J. Sana, A. Besse, T. Loja, M. Vecera, L. Radova, M. Smrcka, P. Slampa, O. Slaby,

. 2017 ; 37 (3) : 1099-1104.

Language English Country Greece

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17023204

Grant support
NV15-33158A MZ0 CEP Register
NV15-34553A MZ0 CEP Register

Glioblastoma multiforme (GBM) is the most aggressive intracranial tumor characterized with infaust prognosis. Despite advances in neurosurgical and radiotherapeutic techniques and chemotherapy, the median overall survival ranges between 12-15 months from diagnosis. The main cause of treatment failure is considered the presence of tumor cells resistant to conventional therapy, mainly radiotherapy. MicroRNAs (miRNAs) are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and have been repeatedly proven to play important roles in pathogenesis and biological features of many cancers, including GBM and its radioresistant phenotype. In our study, we established radioresistant cells from the commonly used human GBM cell lines T98G, U87MG and U251. Consequently, we performed global miRNA expression profiling in both radioresistant and parental cell lines and identified 113 miRNAs with significantly different expression (p<0.05) between these two groups (73 miRNAs were up-regulated, 40 miRNAs were down-regulated). Some of these miRNAs have been previously described in relation to ionizing radiation, and others were herein identified for the first time. We believe that after deeper functional investigation of identified miRNAs in relation to radioresistance, these miRNAs present potential predictive biomarkers or therapeutic targets in GBM.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023204
003      
CZ-PrNML
005      
20201116144032.0
007      
ta
008      
170720s2017 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.11422 $2 doi
035    __
$a (PubMed)28314270
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Ondracek, Jakub $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
245    10
$a Global MicroRNA Expression Profiling Identifies Unique MicroRNA Pattern of Radioresistant Glioblastoma Cells / $c J. Ondracek, P. Fadrus, J. Sana, A. Besse, T. Loja, M. Vecera, L. Radova, M. Smrcka, P. Slampa, O. Slaby,
520    9_
$a Glioblastoma multiforme (GBM) is the most aggressive intracranial tumor characterized with infaust prognosis. Despite advances in neurosurgical and radiotherapeutic techniques and chemotherapy, the median overall survival ranges between 12-15 months from diagnosis. The main cause of treatment failure is considered the presence of tumor cells resistant to conventional therapy, mainly radiotherapy. MicroRNAs (miRNAs) are small, non-coding RNAs that function as post-transcriptional regulators of gene expression and have been repeatedly proven to play important roles in pathogenesis and biological features of many cancers, including GBM and its radioresistant phenotype. In our study, we established radioresistant cells from the commonly used human GBM cell lines T98G, U87MG and U251. Consequently, we performed global miRNA expression profiling in both radioresistant and parental cell lines and identified 113 miRNAs with significantly different expression (p<0.05) between these two groups (73 miRNAs were up-regulated, 40 miRNAs were down-regulated). Some of these miRNAs have been previously described in relation to ionizing radiation, and others were herein identified for the first time. We believe that after deeper functional investigation of identified miRNAs in relation to radioresistance, these miRNAs present potential predictive biomarkers or therapeutic targets in GBM.
650    _2
$a apoptóza $7 D017209
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a nádory mozku $x genetika $x patologie $7 D001932
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $7 D049109
650    _2
$a stanovení celkové genové exprese $7 D020869
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a glioblastom $x genetika $x patologie $7 D005909
650    _2
$a lidé $7 D006801
650    _2
$a mikro RNA $x genetika $7 D035683
650    _2
$a sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů $7 D020411
650    _2
$a fenotyp $7 D010641
650    _2
$a prognóza $7 D011379
650    _2
$a tolerance záření $x genetika $7 D011836
655    _2
$a časopisecké články $7 D016428
700    1_
$a Fadrus, Pavel $u Department of Neurosurgery, University Hospital Brno, Masaryk University, Brno, Czech Republic.
700    1_
$a Sana, Jiri $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic.
700    1_
$a Besse, Andrej $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
700    1_
$a Loja, Tomas $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
700    1_
$a Vecera, Marek $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
700    1_
$a Radova, Lenka $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic.
700    1_
$a Smrcka, Martin $u Department of Neurosurgery, University Hospital Brno, Masaryk University, Brno, Czech Republic.
700    1_
$a Slampa, Pavel $u Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic.
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology (CEITEC), Masaryk University, Brno, Czech Republic on.slaby@gmail.com. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 37, č. 3 (2017), s. 1099-1104
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28314270 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20201116144030 $b ABA008
999    __
$a ok $b bmc $g 1238885 $s 984117
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 37 $c 3 $d 1099-1104 $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
GRA    __
$a NV15-33158A $p MZ0
GRA    __
$a NV15-34553A $p MZ0
LZP    __
$a Pubmed-20170720

Find record

Citation metrics

Archiving options